EXPRESSION OF BONE MORPHOGENETIC PROTEIN- 2 UNDER SIMVASTATIN THERAPY AFTER CYCLOSPORIN -A- INDUCED ALVEOLAR BONE LOSS IN RATS | ||
| Alexandria Dental Journal | ||
| Article 18, Volume 40, Issue 1, July 2015, Pages 113-119 PDF (531.91 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/adjalexu.2015.58745 | ||
| Authors | ||
| H Samir1; S Shafik2; M Yahia3; N Mamdouh4 | ||
| 1- Master student at the Oral Biology Department, Faculty of Dentistry, Alexandria University | ||
| 2- Professor of Oral Biology, Faculty of Dentistry, Alexandria University | ||
| 3Professor of Histochemistry and Cell Biology, Medical Research Institute, Alexandria University | ||
| 4Lecturer of Oral Biology, Faculty of Dentistry, Alexandria University | ||
| Abstract | ||
| Introduction: Cyclosporin-A- has been used as an immunosuppressant to prevent the rejection of organ transplants. However, alveolar bone loss is an important negative side-effect of this drug. Simvastatin, a hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, is known to inhibit cholesterol biosynthesis. It has advanced effects on bone formation in vivo and in vitro. So, we evaluated the expression of BMP 2 after administration of simvastatin in cyclosporin -A-associated alveolar bone loss in rats. Objective: To evaluate the effect of simvastatin and cyclosporin -A- on Alveolar bone by investigating the expression of Bone Morphogenetic Protein -2 (BMP-2) using Immunohistochemical and Image analysis investigation methods. Materials and methods: 24 adult male albino rats were divided into 3 groups: Group I: control group; 4 rats, Group II: cyclosporine -A- group; 10 rats (10 mg/kg) daily subcutaneous injection, Group III: Cyclosporin –A /Simvastatin group; 10 rats, simvastatin was taken orally daily (20mg/kg/day). Two rats from the control group and 5 rats from each of the studied experimental groups (group II & III) were sacrificed on days 15 and 30 consecutively, and examined using Immunohistochemical method, and Image analysis. Results: Immunohistochemical results revealed strong expression of BMP 2 in osteoblasts, osteocytes after simvastatin administration and weak expression in CsA. The same results were statistically significant in Immunohistochemical Optical Density (IOD) results. Histomorphometrical analysis of bone volume showed a significant increase in bone volume in simvastatin group than CsA group, and significant decrease in CsA than control. Conclusion: we can conclude that Simvastatin counteract the adverse effect of CsA induced alveolar bone loss by induction of BMP 2 in osteoblasts and osteocytes that induced new bone formation. | ||
| Keywords | ||
| Simvastatin; Cyclosporin A; Bone loss; Bone Morphogenitic Protein 2 | ||
|
Statistics Article View: 143 PDF Download: 419 |
||
